Rujiwetpongstorn R, et al. - Given the usual association of reactive neutrophilic dermatoses in adult‐onset immunodeficiency due to interferon‐γ autoantibody (AOID) with concomitant active opportunistic infections, researchers here examined the efficacy and safety of acitretin treatment of reactive neutrophilic dermatoses in AOID. In retrospective review, they assessed 23 patients with AOID who had reactive neutrophilic dermatoses and had undergone treatment with acitretin from January 2008 to December 2018. The patients had 27 episodes of reactive neutrophilic dermatoses (20 episodes of Sweet syndrome and seven episodes of generalized pustular eruption). They identified the median effective dose of acitretin of 10 mg/day and the mean initial response of 5.6 ± 2.3 days. Outcomes establish the potential role of acitretin as one of the therapies of choice for reactive neutrophilic dermatoses in AOID; this is attributable to its favorable response and good tolerability.